Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Soligenix, Inc

Femme et Homme Max 99 ans
Soligenix, Inc MAJ Il y a 4 ans

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY OF THE SAFETY AND EFFICACY OF ORBEC® (ORAL BECLOMETHASONE 17,21-DIPROPIONATE) IN CONJUNCTION WITH TEN DAYS OF HIGH-DOSE PREDNISONE THERAPY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL GRAFT VS. HOST DISEASE The primary objective of this confirmatory, multi-center study is to compare the efficacy, defined as the proportion of subjects who are GVHD treatment successes vs. failures, of an oral BDP regimen c...

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations